Keywords
morbidity
treatment
How to Cite
Abstract
Background. ColoRectal Cancer (CRC) is one of the most common malignant tumors: about a million new cases are diagnosed annually in the world. In Ukraine, the incidence of CRC is 20.5 per 100,000 population. The ratio of mortality and morbidity indicates significant shortcomings in the diagnosis, treatment and prevention of CRC.
Aim. To study theoretical scientific developments regarding the influence of intestinal microbiota on the development of colorectal cancer.
Materials and Methods. In the course of writing the scientific article, a number of modern literary sources and the latest data from scientific Web databases were studied of Science, Scopus, Google Scholar and PubMed, methods of systematic and comparative analysis of the specified problem were applied. Medical and statistical data of scientific publications on morbidity and treatment results in different countries of the world were studied.
Results. According to world statistics, CRC is the third most common in men (10.0% of the total number of malignant neoplasms) and the second most common in women (9.2%). Approximately 45.0% of CRC patients die despite treatment. A high percentage of emergency operations is recorded in elderly patients with chronic accompanying pathology, which is the cause of a large number of postoperative complications ([24.0–80.0] %) and mortality ([11.0–36.0] %). The incidence of CRC in Ukraine is the highest among a number of countries and indicates significant deficiencies in the diagnosis and treatment of patients, as well as in the prevention of this disease. Intestinal microbiota plays an important role in the development of colorectal cancer. Disruption of the functioning of the intestinal microbiota also leads to the development of a significant number of infectious, metabolic, oncological, neurological and endocrine diseases.
Conclusion. The analysis of literary sources and clinical studies of domestic and foreign authors allows us to assert that the microbiota, influencing the immune system, plays an important role in the induction and progression of colorectal cancer.
Keywords: mortality, morbidity, treatment.
Archived: https://doi.org/10.5281/zenodo.14392226
References
Boiko VV, Lykhman VM, Shevchenko AM, Merkulov AO, Osmanov RR. The use of minimally invasive operations in the treatment of patients with colorectal cancer complications with intestinal obstruction. 2018;24(2):16-9. Available at: http://jnas.nbuv.gov.ua/j-pdf/Mmzh_2018_24_2_5.pdf [in Ukrainian].
Zakharash MP, Kharchenko NV, Muzyka SV. Screening for precancerous lesions and colon cancer. Methodical recommendations. Kyiv: Medicine; 2010. 18 p.
Tkach SM, Puchkov KS, Syzenko AK. Intestinal microbiota in norm and pathology. Modern approaches to diagnostics and treatment of intestinal dysbiosis. Kyiv: Tvisa LTD; 2014. 149 p.
Fedorenko ZP, Kolesnik OO, Gulak LO, Ryzhov AYu , Sumkina OV. Colorectal cancer in Ukraine: the epidemiological and organizational aspects of the problem. Practical oncology. 2019;2(2):2-9. DOI: 10.22141/2663-3272.2.2.2019.176026. [In Ukrainian].
American Cancer Society. Colorectal Cancer Facts & Figures 2017–2019. Atlanta: American Cancer Society; 2017. 36 p.
Makkouk A, Weiner GJ. Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge. Cancer Res. 2015;75(1):5-10. DOI: 10.1158/0008-5472.CAN-14-2538. PMID: 25524899.
Irrazabal T, Belcheva A, Girardin SE, Martin A, Philpott DJ. The multifaceted role of the intestinal microbiota in colon cancer. Mol Cell. 2014;54(2):309-20. DOI: 10.1016/j.molcel.2014.03.039. PMID: 24766895.
Clark CR, Starr TK. Mouse models for the discovery of colorectal cancer driver genes. World J Gastroenterol. 2016;22(2):815-22. DOI: 10.3748/wjg.v22.i2.815. PMID: 26811627.
McDermott AJ, Huffnagle GB. The microbiome and regulation of mucosal immunity. Immunology. 2014;142(1):24-31. DOI: 10.1111/imm.12231. PMID: 24329495.
Ha CW, Lam YY, Holmes AJ. Mechanistic links between gut microbial community dynamics, microbial functions and metabolic health. World J Gastroenterol. 2014;20(44):16498-517. DOI: 10.3748/wjg.v20.i44.16498. PMID: 25469018.
Gill SR, Pop M, Deboy RT, Eckburg PB, Turnbaugh PJ, Samuel BS, et al. Metagenomic analysis of the human distal gut microbiome. Science. 2006;312(5778):1355-9. DOI: 10.1126/science.1124234. PMID: 16741115.
Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L, Kunkler I; EUROCARE-4 Working Group. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol. 2007;8(9):784-96. DOI: 10.1016/S1470-2045(07)70246-2. Erratum in: Lancet Oncol. 2008;9(5):416. PMID: 17714993.
Flint HJ, Scott KP, Louis P, Duncan SH. The role of the gut microbiota in nutrition and health. Nat Rev Gastroenterol Hepatol. 2012;9(10):577-89. DOI: 10.1038/nrgastro.2012.156. PMID: 22945443.
Ley RE, Turnbaugh PJ, Klein S, Gordon JI. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-3. DOI: 10.1038/4441022a. PMID: 17183309.
Durban A, Abellan JJ, Jimenez-Hernandez N, Ponce M, Ponce J, Sala T, et al. Assessing gut microbial diversity from feces and rectal mucosa. Microb Ecol. 2011;61(1):123-33. DOI: 10.1007/s00248-010-9738-y. PMID: 20734040.
Prakash S, Rodes L, Coussa -Charley M, Tomaro-Duchesneau C. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics. 2011;5:71-86. DOI: 10.2147/BTT.S19099. PMID: 21847343.
Gagniere J, Raisch J, Veziant J, Barnich N, Bonnet R, Buc E, et al. Gut microbiota imbalance and colorectal cancer. World J Gastroenterol. 2016;22(2):501-18. DOI: 10.3748/wjg.v22.i2.501. PMID: 26811603.
Jandhyala SM, Talukdar R, Subramanyam C, Vuyyuru H, Sasikala M, Nageshwar Reddy D. Role of the normal gut microbiota. World J Gastroenterol. 2015;21(29):8787-803. DOI: 10.3748/wjg.v21.i29.8787. PMID: 26269668.
Wu N, Yang X, Zhang R, Li J, Xiao X, Hu Y, et al. Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol. 2013;66(2):462-70. DOI: 10.1007/s00248-013-0245-9. PMID: 23733170.
Toprak NU, Yagci A, Gulluoglu BM, Akin ML, Demirkalem P, Celenk T, Soyletir G. A possible role of Bacteroides fragilis enterotoxin in the etiology of colorectal cancer. Clin Microbiol Infect. 2006;12(8):782-6. DOI: 10.1111/j.1469-0691.2006. 01494.x. PMID: 16842574.
McCoy AN, Araujo-Perez F, Azcarate -Peril A, Yeh JJ, Sandler RS, Keku TO. Fusobacterium is associated with colorectal adenomas. PLoS One. 2013;8(1):e53653. DOI: 10.1371/journal.pone.0053653. PMID: 23335968.
Koropatkin NM, Cameron EA, Martens EC. How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol. 2012;10(5):323-35. DOI: 10.1038/nrmicro2746. PMID: 22491358.
Boleij A, Tjalsma H. The itinerary of Streptococcus gallolyticus infection in patients with colonic malignant disease. Lancet Infect Dis. 2013;13(8):719-24. DOI: 10.1016/S1473-3099(13)70107-5. PMID: 23831427.
Klein RS, Recco RA, Catalano MT, Edberg SC, Casey JI, Steigbigel NH. Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med. 1977;297(15):800-2. DOI: 10.1056/NEJM197710132971503. PMID: 408687.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.